Numis Securities Ltd restated their buy rating on shares of Indivior PLC (LON:INDV) in a research report report published on Monday morning. They currently have a GBX 370 ($4.83) price objective on the specialty pharmaceutical company’s stock.
Several other equities research analysts have also issued reports on the company. Jefferies Group raised their price objective on Indivior PLC from GBX 330 ($4.31) to GBX 370 ($4.83) and gave the company a buy rating in a research note on Monday, August 22nd. Deutsche Bank AG raised their price objective on Indivior PLC from GBX 340 ($4.44) to GBX 400 ($5.22) and gave the company a buy rating in a research note on Thursday, August 18th. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 350 ($4.57) price objective on shares of Indivior PLC in a research note on Wednesday, August 17th. Royal Bank Of Canada raised their price objective on Indivior PLC from GBX 185 ($2.41) to GBX 325 ($4.24) and gave the company a sector performer rating in a research note on Tuesday, August 9th. Finally, Morgan Stanley increased their price target on Indivior PLC from GBX 280 ($3.65) to GBX 330 ($4.31) and gave the stock an overweight rating in a report on Monday, August 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of GBX 346.43 ($4.52).
Shares of Indivior PLC (LON:INDV) opened at 305.00 on Monday. The company’s market capitalization is GBX 2.20 billion. The firm has a 50-day moving average price of GBX 317.29 and a 200 day moving average price of GBX 233.75. Indivior PLC has a 12-month low of GBX 126.60 and a 12-month high of GBX 365.00.
Indivior PLC Company Profile
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.